Jun Zhang, MD, PhD
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.
Inclusion Criteria: * Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent * Participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up * Life expectancy ≥12 weeks * Males and females age ≥ 18 years * Allowable type and amount of prior therapy: Participants must have received two or more cycles of platinum-based chemotherapy (containing etoposide, vinblastine, vinore…
Arctuva estimate
Verify or correct the compensation shown for this listing.